Study guide
4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation
NCC Inpatient Obstetric Nursing RNC-OB
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: Introduction & How to Use This Guide
0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology
2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions
1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders
3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders
2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications
4 Chapter 3: Antenatal Fetal Assessment & Surveillance
3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation
5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)
4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation
6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support
5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices
7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia
6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia
8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures
7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation
9 Chapter 8: Obstetric Emergencies & Critical Care
8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis
10 Chapter 9: Postpartum Physiology & Immediate Recovery Care
9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety
11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications
10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety
12 Chapter 11: Newborn Care, Transition & Clinical Assessment
11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants
13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management
12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)
14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement
13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines
4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation
Key Takeaways Explain This Topic AI
Fetal cardiac arrhythmias complicate 1% to 2% of pregnancies; they are classified into irregular rhythms (extrasystoles), tachyarrhythmias (heart rate >160–180 bpm), and bradyarrhythmias (heart rate <110 bpm).
Premature atrial contractions (PACs) represent >85% of all fetal arrhythmias; they appear as sharp vertical spikes or brief drop-offs on EFM with preserved normal baseline and variability, are overwhelmingly benign and self-limiting, but carry a 1% to 2% risk of triggering supraventricular tachycardia (SVT).
Sustained fetal supraventricular tachycardia (SVT, rate 210–260+ bpm) impairs diastolic ventricular filling, decreases cardiac output, elevates systemic venous pressures, and causes non-immune hydrops fetalis (pleural effusions, ascites, skin edema) and intrauterine demise; transplacental treatment includes digoxin, flecainide, or sotalol.
Complete (third-degree) congenital atrioventricular heart block (CAVB, fixed ventricular rate 50–80 bpm) is strongly associated with maternal anti-Ro/SSA and anti-La/SSB autoantibodies crossing the placenta to cause autoimmune fibrosis of the fetal AV node.
Maternal heart rate (MHR) artifact occurs when an external ultrasound transducer erroneously tracks maternal pelvic vessels rather than the fetal heart, typically manifesting as an apparent 'deceleration' or 'acceleration' that mirrors maternal pulse; confirmation requires simultaneous maternal pulse oximetry or placement of a fetal scalp electrode (FSE).
Last updated: August 2026
Electrophysiology and Classification of Fetal Arrhythmias
Fetal cardiac arrhythmias occur in approximately 1% to 2% of all pregnancies and account for 10% to 20% of referrals to maternal-fetal medicine specialists. While the vast majority represent benign, transient conduction delays, sustained fetal tachyarrhythmias and bradyarrhythmias can lead to cardiovascular collapse, non-immune hydrops fetalis, and intrauterine demise. +-------------------------------------------------------------------------------------------------------------------+
| CLASSIFICATION OF FETAL CARDIAC ARRHYTHMIAS |
+-------------------------------------------------------------------------------------------------------------------+
- |
- +-----------------------------------------------+-----------------------------------------------+
- | | |
- v v v
- [ IRREGULAR RHYTHMS ] [ TACHYARRHYTHMIAS ] [ BRADYARRHYTHMIAS ]
- Premature Atrial Contractions - Supraventricular Tachycardia (SVT) - Complete (3rd Degree) AV Block
- (PACs / APCs) [>85% of cases] (Rate 210 to 260+ bpm) (Ventricular rate 50-80 bpm)
- Premature Ventricular Contractions - Atrial Flutter - Sinus Bradycardia (<110 bpm)
- (PVCs / VPCs) (Atrial 300-500, Ventric 150-240) - Blocked Atrial Bigeminy
- Benign, self-limiting (>98%) - Risk: Non-Immune Hydrops Fetalis - Linked to maternal anti-Ro/SSA
+-------------------------------------------------------------------------------------------------------------------+
- Irregular Fetal Rhythms: PACs and PVCs
- Premature Atrial Contractions (PACs)
Epidemiology & Electrophysiology: PACs (also called atrial premature beats) represent >85% to 90% of all diagnosed fetal arrhythmias. They originate from an irritable ectopic atrial pacemaker firing prematurely before the sinoatrial (SA) node discharges, reflecting electrophysiological immaturity of the developing conduction system.
EFM Tracing Appearance: On continuous electronic fetal monitoring, PACs appear as sudden, sharp, vertical "spikes" shooting above the baseline (conducted PACs) or brief downward tick marks / drop-offs (blocked/non-conducted PACs). The underlying baseline FHR rate and baseline variability remain completely normal .
Clinical Prognosis & Management: Over 98% of fetal PACs are benign and self-limiting , resolving spontaneously in the late third trimester or within the first 1 to 2 weeks of neonatal life. However, in 1% to 2% of cases , frequent PACs (especially atrial bigeminy or trigeminy) can trigger sustained re-entrant Supraventricular Tachycardia (SVT) . Inpatient nursing care involves serial auscultation, monitoring for sustained rate acceleration, and avoidance of maternal caffeine and sympathomimetics.
Premature Ventricular Contractions (PVCs)
Originates from an ectopic ventricular focus below the AV node. Characterized by an irregular rhythm with a fully compensatory pause. Less common than PACs and typically benign, but requires postnatal 12-lead ECG to rule out long QT syndrome or structural cardiomyopathy.
Fetal Tachyarrhythmias: SVT and Atrial Flutter +-------------------------------------------------------------------------------------------------------------------+
| FETAL TACHYARRHYTHMIA COMPARISON TABLE |
+-------------------------------------------------------------------------------------------------------------------+
Arrhythmia Type Ventricular Rate Range Rhythm & Variability Features Hemodynamic Risks & Management
-------------------- ------------------------ ---------------------------------- -------------------------------
Supraventricular 210 to 260+ bpm Abrupt, step-like onset & offset; Loss of diastolic filling time;
Tachycardia (SVT) (Fixed, monotonous) ABSENT baseline variability during Non-Immune Hydrops; First-line:
paroxysms; 1:1 AV conduction Digoxin, Flecainide, Sotalol
-------------------- ------------------------ ---------------------------------- -------------------------------
Atrial Flutter 150 to 240 bpm Sawtooth atrial flutter waves on High cardiac output failure;
(Atrial: 300 to 500 bpm) echocardiography; 2:1 or 3:1 AV Hydrops risk; First-line:
conduction block Sotalol or Flecainide
-------------------- ------------------------ ---------------------------------- -------------------------------
- Sinus Tachycardia 161 to 180 (rarely >190) Gradual onset & resolution; Infection, fever, anemia, drug;
- Preserved moderate variability Treat underlying maternal cause
+-------------------------------------------------------------------------------------------------------------------+
Pathophysiology of Supraventricular Tachycardia (SVT) and Hydrops Fetalis
Sustained SVT (>50% of the monitoring time) is a life-threatening fetal cardiac emergency. At ventricular rates of 220 to 260 bpm:
Loss of Diastolic Ventricular Filling: Extreme tachycardia severely curtails the diastolic filling period of both ventricles, reducing end-diastolic volume and stroke volume.
Elevated Central Venous Pressure: Back-pressure into the right atrium, inferior vena cava, and hepatic veins produces marked systemic venous congestion and elevated capillary hydrostatic pressure.
Myocardial Ischemia: Diminished coronary arterial perfusion pressure combined with extreme myocardial oxygen demand leads to cardiac enlargement and progressive biventricular congestive heart failure.
Development of Non-Immune Hydrops Fetalis: Fluid extravasates into interstitial tissues and fetal body cavities, manifesting as pleural effusions, pericardial effusions, ascites, polyhydramnios, and scalp/skin edema (defined as fluid accumulation in >=2 fetal compartments). +-------------------------------------------------------------------------------------------------------------------+
| PATHOPHYSIOLOGICAL CASCADE: SUSTAINED SVT TO HYDROPS FETALIS |
+-------------------------------------------------------------------------------------------------------------------+
- [ Sustained Fetal SVT (220-260 bpm) ]
- |
- v
- [ Shortened Diastolic Ventricular Filling Time ] ---> [ Decreased Cardiac Output & Stroke Volume ]
- |
- v
- [ Severe Systemic Venous Congestion & High CVP ] ---> [ Hepatic Congestion & Decreased Albumin Synthesis ]
- |
- v
- [ Capillary Hydrostatic Fluid Extravasation ]
- |
- v
- [ NON-IMMUNE HYDROPS FETALIS ] ---> (Pleural Effusions + Pericardial Effusion + Ascites + Scalp Edema)
- |
- v
- [ Intrauterine Fetal Demise / Severe Neonatal Compromise ]
+-------------------------------------------------------------------------------------------------------------------+
Transplacental Antiarrhythmic Pharmacotherapy
Digoxin: Historically first-line agent. Increases myocardial vagal tone and slows AV nodal conduction. Crosses the placenta well in non-hydropic fetuses (maternal therapeutic serum level: 1.0 to 2.0 ng/mL ). However, placental transfer is markedly impaired in hydropic fetuses.
Flecainide: Class IC antiarrhythmic. Drug of choice for SVT with established hydrops fetalis due to superior transplacental penetration and high cardioversion rates (>80–90%).
Sotalol: Class III beta-blocker/potassium-channel blocker. First-line agent for fetal Atrial Flutter .
- Fetal Bradyarrhythmias: Complete Congenital Heart Block
- Complete (Third-Degree) Atrioventricular Block (CAVB)
Clinical Presentation: Persistent, fixed fetal heart rate between 50 and 80 bpm with complete dissociation between atrial and ventricular depolarizations on fetal echocardiography. The ventricular rate is completely unresponsive to maternal movement or uterine contractions.
Autoimmune Etiology (Maternal Anti-Ro/SSA & Anti-La/SSB Antibodies):
In approximately 50% of cases , complete heart block is caused by transplacental transfer of maternal IgG autoantibodies (anti-Ro/SSA and anti-La/SSB) in mothers with Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, or asymptomatic carriers.
Mechanism: Maternal IgG antibodies cross the placenta between 16 and 24 weeks of gestation, bind directly to L-type calcium channels in the fetal cardiac conduction system, and trigger autoimmune myocarditis, macrophage infiltration, irreversible calcification, and fibrotic destruction of the fetal AV node and bundle of His .
Structural Etiology: The remaining 50% of cases are associated with major congenital structural cardiac malformations (e.g., L-transposition of the great arteries, atrioventricular septal defects).
Management & Prognosis: Once complete third-degree heart block is established, it is permanent and irreversible. Maternal treatment with fluorinated corticosteroids ( Dexamethasone 4 mg/day orally ) is used in early/incomplete block to suppress autoimmune myocarditis. Ventricular rates <55 bpm or development of hydrops carries high mortality and requires immediate postnatal permanent cardiac pacemaker implantation.
EFM Artifact Differentiation and Signal Pitfalls
Inpatient obstetric nurses must possess expert skill in distinguishing true fetal cardiac dysrhythmias from electronic monitoring artifacts, equipment signal dropouts, and maternal signal transposition. +-------------------------------------------------------------------------------------------------------------------+
| DIAGNOSTIC MATRIX: FETAL ARRHYTHMIAS VS. EFM ARTIFACTS |
+-------------------------------------------------------------------------------------------------------------------+
Pattern / Finding Underlying Mechanism Distinguishing Features on Strip & Action
---------------------------- ------------------------------------ -----------------------------------------------
Maternal Heart Rate (MHR) Ultrasound transducer tracks maternal Rate is 70 to 100 bpm; shows acute accelerations
- Transposition iliac artery or aortic pulsation coinciding exactly with contractions/pushing;
- Verify maternal pulse with pulse oximeter
---------------------------- ------------------------------------ -----------------------------------------------
- Double-Counting Artifact Ultrasound machine counts both S1 Sudden jump from baseline (e.g., 75 bpm -> 150)
- and S2 heart sounds or tall T-waves No clinical distress; switch to FSE
---------------------------- ------------------------------------ -----------------------------------------------
- Half-Counting Artifact Ultrasound machine fails to capture True rate is severe tachycardia (e.g., 220 bpm)
- every beat in rapid tachycardias displayed as 110 bpm; auscultate heart rate stat
---------------------------- ------------------------------------ -----------------------------------------------
- Signal Dropout / Gap Loss of acoustic ultrasound beam Blank horizontal gaps in strip; adjust toco /
- contact (maternal habitus/movement) re-position transducer or place scalp electrode
+-------------------------------------------------------------------------------------------------------------------+
1. Maternal Heart Rate (MHR) Transposition
Mechanism: The external Doppler ultrasound transducer inadvertently locks onto the pulsating maternal common iliac artery or descending aorta rather than the fetal heart.
Classic Clinical Presentation: The tracing displays an apparent baseline rate between 70 and 100 bpm that exhibits sudden "accelerations" synchronized exactly with each uterine contraction or maternal pushing effort (as maternal heart rate spikes with exertion and pain). When the contraction ends, the heart rate drops back to 70–80 bpm, mimicking a profound deceleration.
Nursing Confirmation: Immediately check the maternal radial pulse or place a continuous maternal pulse oximeter that integrates with the central EFM system. If the maternal pulse and the monitor rate match beat-for-beat, MHR transposition is confirmed.
2. Double-Counting and Half-Counting Artifacts
Double-Counting: When the fetal heart rate is slow (bradycardia 60–80 bpm), the ultrasound machine may detect both the first heart sound (S1, mitral/tricuspid closure) and the second heart sound (S2, aortic/pulmonic closure) as separate cycles, displaying an artificial baseline of 120–160 bpm.
Half-Counting: When the fetal heart rate is extremely rapid (SVT 220–260 bpm), the machine's processing algorithm may fail to register every alternating cycle, artificially displaying the rate at half its true value (e.g., 110–130 bpm).
3. Fetal Scalp Electrode (FSE / Spiral Electrode)
An internal fetal scalp electrode provides direct electrocardiographic (ECG) detection of the fetal R-to-R wave intervals, eliminating ultrasound acoustic artifact and providing true beat-to-beat variability measurement. +-------------------------------------------------------------------------------------------------------------------+
| FETAL SCALP ELECTRODE (FSE) PREREQUISITES & CONTRAINDICATIONS |
+-------------------------------------------------------------------------------------------------------------------+
MANDATORY CLINICAL PREREQUISITES: ABSOLUTE CLINICAL CONTRAINDICATIONS:
- 1. Ruptured amniotic membranes (spontaneous or artificial) 1. Maternal HIV infection
- 2. Adequate cervical dilation (at least 1 to 2 cm) 2. Active maternal Hepatitis B or Hepatitis C virus
- 3. Accessible fetal presenting part 3. Active maternal genital Herpes Simplex Virus (HSV)
- 4. Confirmed cephalic presentation (avoid face, eyes, 4. Severe fetal bleeding diathesis (Hemophilia, vWD)
- fontanelles, or genitalia in breech) 5. Unconfirmed presenting part or placenta previa
+-------------------------------------------------------------------------------------------------------------------+